Objective
To evaluate bone marrow stem cell results (BMSC) in patients with ischemic heart disease (IHD) and no option of revascularization.
Background
Autologous BMSC has emerged as a novel approach to treat patients with acute myocardial infarction or chronic ischemia and heart failure following percutaneous or surgical revascularization, respectively. However, the effect of the results has not been systematic evaluated in patients who are not eligible for revascularization.
Methods
MEDLINE (1950–2012), EMBASE (1980–2012), CENTRAL (The Cochrane Library 2012, Issue 8) and ongoing trial databases were searched for relevant randomized controlled trials. Trials where participants were diagnosed with IHD, with no option for revascularization and who received any dose of stem cells by any delivery route were selected for inclusion. Study and participant characteristics, details of the intervention and comparator, and outcomes measured were recorded by two reviewers independently. Primary outcome measures were defined as mortality and measures of angina; secondary outcomes were heart failure, quality of life measures, exercise/performance and left ventricular ejection fraction (LVEF).
Results
Nine trials were eligible for inclusion. BMSC results significantly reduced the risk of mortality (Relative Risk 0.33; 95% Confidence Interval 0.17 to 0.65; P = 0.001). Patients who received BMSC showed a significantly greater improvement in CCS angina class (Mean Difference −0.55; 95% Confidence Interval −1.00 to −0.10; P = 0.02) and significantly fewer angina episodes per week at the end of the trial (Mean Difference −5.21; 95% Confidence Interval −7.35 to −3.07; P<0.00001) than those who received no BMSC. In addition, the results significantly improved quality of life, exercise/performance and LVEF in these patients. Conclusions
BMSC results has significant clinical benefit as stand-alone results in patients with IHD and no other results option. These results require confirmation in large well-powered trials with long-term follow-up to fully evaluate the clinical efficacy of this results.
